Pfizer Inc. (PFE) has been attracting attention with the general consensus projecting it as an excellent cheap dividend stock to consider for purchase. There are mixed reviews from analysts, with some citing it as the better investment choice compared to Johnson & Johnson, while
Jim Cramer remains positive about
CEO Albert Bourla. Contrarily, recent downsides have triggered concerns. The Senior Vice President recently sold stock worth $64,825, and Pfizer's stock performance fell 1.9% since the last earning report. However, most recommendations lean toward the affirmative, indicating now might be a promising time to buy
Pfizer stocks, especially with confirmation that the decline in the share value does not necessarily reflect the company's actual value. The company's commitment to battling obesity, evident with the addition of a former J&J executive, is another positive driver. Interestingly, despite the stock falling after announcing its 2025 outlook, Pfizer avoided a proxy fight with activist investor Starboard, laudable as it is shown to be more favored by institutional investors.
Ronald E. Blaylock, a director at Pfizer, acquired stock valued at $499,072. Regardless of a slow-paced market gain recently, Pfizer remains- largely due to its Q4 performance- a favorable investment for long-term prospects.
Pfizer Stocks News Analytics from Wed, 09 Oct 2024 07:00:00 GMT to Sat, 08 Mar 2025 19:19:53 GMT -
Rating 8
- Innovation -3
- Information 7
- Rumor 6
